Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 1050 in its research report ...

KR Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1201 in its ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Earnings: Zydus Lifesciences reported a 30% YoY rise in Q3FY25 net profit to ₹1,023.5 crore, driven by strong US growth.

Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...